they were scammin. the reason they got a license to only grow 30k lbs per year was because they had these intentions all along.TWEED was having whole plants shipped in so they could flip it for a profit. terrible business model, it will only help FITX because Creative Edge will crush little companies like this once production starts.
(0)
(0)
Creative Edge Nutrition Inc. (FITX) Stock Research Links
XO Enhances Private Aviation Network with More Booking OptionsXO, a prominent player in the private aviation sector under the Vista group, is taking considerable strides to improve how clients book private flights. With a remarkable increase in the number of jets available for instant booking by over 55%, the company is positioning itself to address the growing demand for more accessible private air travel options.Unlocking Instant Booking FeaturesBy expanding its ins... Continue Reading
Frozen Dough Market Growth OverviewThe frozen dough market is expected to achieve a remarkable valuation of USD 41.9 billion in the coming years, indicating a robust growth trajectory. This market specializes in producing and selling ready-to-bake dough that is preserved using freezing methods to enhance shelf life and provide convenience for users.Trends Driving Demand for Frozen DoughIn today’s fast-paced world, many consumers are looking for quick and convenient me... Continue Reading
Dynamic Growth of the Cryogenic Ethylene Market
According to research, the global cryogenic ethylene market is estimated to reach a valuation of US$ 5,706.9 million in the immediate future and is projected to witness impressive growth, with a compound annual growth rate (CAGR) of 9.2% through the next decade. This substantial growth can be attributed to the rising demand for polyethylene, a versatile plastic extensively utilized in packaging, constru... Continue Reading
BeiGene's TEVIMBRA® Achieves Milestone for Cancer Therapy
BeiGene, Ltd. (NASDAQ: BGNE), a prominent player in the global oncology landscape, has received positive opinions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. These opinions endorse the extended authorization for TEVIMBRA® (tislelizumab) as a first-line treatment for advanced gastric or gastroesophageal junction cancer and esophageal squamous cell carcinoma (ESCC).
De... Continue Reading
Zymeworks Unveils Phase 1 Clinical Trial for ZW171In an exciting development for the biotechnology sector, Zymeworks Inc. has announced the initiation of their Phase 1 clinical trial of ZW171, a cutting-edge therapy aimed at treating advanced mesothelin-expressing cancers. This trial is particularly focused on ovarian cancer and non-small cell lung cancer (NSCLC), among other malignancies, where mesothelin expression is prevalent.Understanding Mesothelin in Cancer Treatment... Continue Reading
Bruker Corporation's Innovations in Deep ProteomicsAt the forefront of scientific advancement, Bruker Corporation (Nasdaq: BRKR) is transforming the field of proteomics with its recent announcements regarding deep, high-accuracy plasma proteome profiling. This breakthrough enables comprehensive studies with unprecedented fidelity and efficiency, particularly beneficial for broad-scale research. The advancements, showcased at a significant global congress, highlight Bruker’s ongoing c... Continue Reading
Tower Semiconductor to Announce Third Quarter Financial Results
Tower Semiconductor (NASDAQ/TASE: TSEM), recognized as a leader in high-value analog semiconductor solutions, is gearing up to share its third-quarter financial results with investors. The anticipated earnings release is scheduled for November 13.
Details on the Conference Call
A conference call will follow the earnings announcement to discuss financial outcomes and guidance for the fourth quarter of the... Continue Reading
Endospan Completes Enrollment of Primary Arm in TRIOMPHE Study
Endospan, a leader in endovascular solutions for aortic arch disease, has proudly announced the completion of patient enrollment for the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical study targeting the NEXUS® Aortic Arch Stent Graft. This study is critical in assessing the safety and effectiveness of the device in treating patients with aortic arch disease.
About the NEXUS Aortic Arc... Continue Reading
Grab Holdings Plans to Reveal Q3 2024 Results Soon
Grab Holdings Limited (NASDAQ: GRAB) is gearing up to share its financial performance for the third quarter of 2024. This announcement is expected to occur after the U.S. market closes, allowing investors and analysts a first look at the Company's performance metrics for this period.
Conference Call Information
Management will host a conference call where they will dive into the results of Q3 2024. This discussion is... Continue Reading
SunHydrogen's Pilot Demonstration: A New Era in Hydrogen Technology
SunHydrogen, Inc. (OTCQB: HYSR), is at the forefront of innovation in the renewable energy sector, focusing on the development of sustainable hydrogen production using its remarkable green hydrogen panels. As the company moves forward, it has taken significant steps toward a critical milestone: a 1m² scale pilot demonstration of these panels.
Collaboration with Industry Leaders
In an exciting develop... Continue Reading